BOLT Bolt Biotherapeutics

USD 1.22 0.03 2.521008
Icon

Bolt Biotherapeutics (BOLT) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.22

+0.03 (+2.52)%

USD 0.04B

0.05M

USD 6.50(+432.79%)

N/A

Icon

BOLT

Bolt Biotherapeutics (USD)
COMMON STOCK | NSD
USD 1.22
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.04B

N/A

USD 1.22

Bolt Biotherapeutics (BOLT) Stock Forecast

Show ratings and price targets of :
USD 6.50
(+432.79%)

Based on the Bolt Biotherapeutics stock forecast from 2 analysts, the average analyst target price for Bolt Biotherapeutics is USD 6.50 over the next 12 months. Bolt Biotherapeutics’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bolt Biotherapeutics is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Bolt Biotherapeutics’s stock price was USD 1.22. Bolt Biotherapeutics’s stock price has changed by +5.17% over the past week, +1.67% over the past month and -8.96% over the last year.

No recent analyst target price found for Bolt Biotherapeutics
No recent average analyst rating found for Bolt Biotherapeutics

Company Overview Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal gro...Read More

https://www.boltbio.com

900 Chesapeake Drive, Redwood City, CA, United States, 94063

94

December

USD

USA

Adjusted Closing Price for Bolt Biotherapeutics (BOLT)

Loading...

Unadjusted Closing Price for Bolt Biotherapeutics (BOLT)

Loading...

Share Trading Volume for Bolt Biotherapeutics Shares

Loading...

Compare Performance of Bolt Biotherapeutics Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BOLT

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Bolt Biotherapeutics (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.14 (-0.27%) USD107.38B 29.93 21.06

ETFs Containing BOLT

Symbol Name BOLT's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Bolt Biotherapeutics (BOLT) Stock

Based on ratings from 2 analysts Bolt Biotherapeutics's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.

Unfortunately we do not have enough data on BOLT's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for BOLT is USD 6.50 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 5.

Unfortunately we do not have enough data on BOLT's stock to indicate if its overvalued.

The last closing price of BOLT's stock was USD 1.22.

The most recent market capitalization for BOLT is USD 0.04B.

Based on targets from 2 analysts, the average taret price for BOLT is projected at USD 6.50 over the next 12 months. This means that BOLT's stock price may go up by +432.79% over the next 12 months.

We can't find any ETFs which contains Bolt Biotherapeutics's stock.

As per our most recent records Bolt Biotherapeutics has 94 Employees.

Bolt Biotherapeutics's registered address is 900 Chesapeake Drive, Redwood City, CA, United States, 94063. You can get more information about it from Bolt Biotherapeutics's website at https://www.boltbio.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...